Normal myogenesis and increased apoptosis in myotonic dystrophy type-1 muscle cells

E Loro1, F Rinaldi, A Malena

  • 1Department of Neurosciences, University of Padova, Padova, Italy.

Insights

Myotonic dystrophy type 1 (DM1) muscle wasting stems from premature cell death pathways, not flawed muscle development. Inhibiting apoptosis with Z-VAD treatment preserved muscle cells, suggesting new therapeutic targets for DM1.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cell Biology

Background:

  • Myotonic dystrophy (DM) arises from a CTG repeat expansion in the DMPK gene's 3'-UTR.
  • This leads to nuclear RNA foci, sequestering proteins and disrupting alternative splicing.
  • The exact cause of muscle distress in DM1, including atrophy, remains debated.

Purpose of the Study:

  • To investigate the in vitro differentiation and maturation of myotubes from DM1 patients.
  • To determine the underlying mechanisms of muscle wasting in DM1.
  • To explore potential therapeutic interventions targeting cell death pathways.

Main Methods:

  • Differentiated primary human DM1 and control myoblasts into myotubes.
  • Utilized morphological, immunohistochemical, RT-PCR, and Western blotting analyses.
  • Confirmed CTG expansions and assessed splicing alterations, apoptosis, and autophagy markers.
  • Administered Z-VAD, a caspase inhibitor, to evaluate its effects on myotube integrity.

Main Results:

  • DM1 myotubes exhibited normal differentiation and maturation compared to controls.
  • Confirmed CTG expansions and aberrant splicing of insulin receptor and MBNL1 genes in DM1 cells.
  • Observed significant myotube loss and atrophy in DM1 cultures, indicative of activated apoptosis and autophagy.
  • Z-VAD treatment partially rescued myonuclei number and myotube width, reducing cell loss.

Conclusions:

  • Muscle wasting in DM1 is primarily driven by premature activation of apoptotic and autophagic pathways, not impaired myogenesis.
  • These catabolic pathways disrupt muscle mass maintenance and regeneration.
  • Targeting apoptosis offers a potential therapeutic strategy for mitigating muscle wasting in DM1.

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Formation of Muscle Fibers from Myoblasts01:13

Formation of Muscle Fibers from Myoblasts

De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription factors...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...